Consolidation Immunotherapy After Platinum-Based Chemoradiotherapy in Patients With Unresectable Stage III Non-Small Cell Lung Cancer—Cross-Sectional Study of Eligibility and Administration Rates

INTRODUCTION: The PACIFC trial demonstrated a significant benefit of durvalumab consolidation immunotherapy (CIT) after definitive platinum-based chemoradiotherapy (P-CRT) for survival in stage III non-small cell lung cancer (NSCLC). It is unknown how many patients are eligible in clinical practice...

Descripción completa

Detalles Bibliográficos
Autores principales: Eichkorn, Tanja, Bozorgmehr, Farastuk, Regnery, Sebastian, Dinges, Lisa A., Kudak, Andreas, Bougatf, Nina, Weber, Dorothea, Christopoulos, Petros, Muley, Thomas, Kobinger, Sonja, König, Laila, Hörner-Rieber, Juliane, Adeberg, Sebastian, Heussel, Claus Peter, Thomas, Michael, Debus, Jürgen, El Shafie, Rami A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7736629/
https://www.ncbi.nlm.nih.gov/pubmed/33335856
http://dx.doi.org/10.3389/fonc.2020.586449

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7736629/
https://www.ncbi.nlm.nih.gov/pubmed/33335856
http://dx.doi.org/10.3389/fonc.2020.586449

Ejemplares similares